Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Epithelium

News

Helsinn Healthcare And Zealand Pharma Sign A Partnering Agreement For ZP1846, A Novel GLP-2 Agonist

Published December 2, 2008, 2:06 am, ChemicalOnline

Helsinn Healthcare's Top management recently announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of ...

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Epithelium Stories

From Various News Sources

Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ... - Genetic Engineering News
Zealand Pharma A/S and Helsinn Healthcare SA today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to ...

Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ... - Genetic Engineering News
Breaking News Email Print Back Share Nov 26 2008, 11:16 PM EST Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist PRNEWSWIRE LUGANO, Switzerland , November 27 /PRNewswire/ -- Helsinn Healthcare's Top ...

Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ... - Genetic Engineering News
Zealand Pharma A/S and Helsinn Healthcare SA today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to ...

Related Social Bookmarks

None found at this time.